These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26478198)

  • 1. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A.
    Stylianou E; Griffiths KL; Poyntz HC; Harrington-Kandt R; Dicks MD; Stockdale L; Betts G; McShane H
    Vaccine; 2015 Nov; 33(48):6800-8. PubMed ID: 26478198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
    Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
    J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis.
    Pérez de Val B; Villarreal-Ramos B; Nofrarías M; López-Soria S; Romera N; Singh M; Abad FX; Xing Z; Vordermeier HM; Domingo M
    Clin Vaccine Immunol; 2012 Sep; 19(9):1339-47. PubMed ID: 22761299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
    Vordermeier HM; Villarreal-Ramos B; Cockle PJ; McAulay M; Rhodes SG; Thacker T; Gilbert SC; McShane H; Hill AV; Xing Z; Hewinson RG
    Infect Immun; 2009 Aug; 77(8):3364-73. PubMed ID: 19487476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice.
    Chen Z; Gupta T; Xu P; Phan S; Pickar A; Yau W; Karls RK; Quinn FD; Sakamoto K; He B
    Vaccine; 2015 Dec; 33(51):7217-7224. PubMed ID: 26552000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice.
    Britton G; MacDonald DC; Brown JS; Collins MK; Goodman AL
    Immunology; 2015 Oct; 146(2):264-70. PubMed ID: 26095282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
    Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
    Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
    McShane H; Pathan AA; Sander CR; Keating SM; Gilbert SC; Huygen K; Fletcher HA; Hill AV
    Nat Med; 2004 Nov; 10(11):1240-4. PubMed ID: 15502839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential pulmonary immunization with heterologous recombinant influenza A virus tuberculosis vaccines protects against murine M. tuberculosis infection.
    Muflihah H; Flórido M; Lin LCW; Xia Y; Triccas JA; Stambas J; Britton WJ
    Vaccine; 2018 Apr; 36(18):2462-2470. PubMed ID: 29602704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model.
    Pinpathomrat N; Bull N; Pasricha J; Harrington-Kandt R; McShane H; Stylianou E
    Vaccine; 2021 Mar; 39(9):1452-1462. PubMed ID: 33549390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future?
    Smaill F; Xing Z
    Expert Rev Vaccines; 2014 Aug; 13(8):927-30. PubMed ID: 24935214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
    Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
    Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen.
    Santosuosso M; Zhang X; McCormick S; Wang J; Hitt M; Xing Z
    J Immunol; 2005 Jun; 174(12):7986-94. PubMed ID: 15944305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis.
    You Q; Jiang C; Wu Y; Yu X; Chen Y; Zhang X; Wei W; Wang Y; Tang Z; Jiang D; Wu Y; Wang C; Meng X; Zhao X; Kong W
    Scand J Immunol; 2012 Jan; 75(1):77-84. PubMed ID: 21916923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
    Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Isaacs F; Keyser A; Moyo S; Brittain N; Lawrie A; Gelderbloem S; Veldsman A; Hatherill M; Hawkridge A; Hill AV; Hussey GD; Mahomed H; McShane H; Hanekom WA
    Eur J Immunol; 2010 Jan; 40(1):279-90. PubMed ID: 20017188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
    Betts G; Poyntz H; Stylianou E; Reyes-Sandoval A; Cottingham M; Hill A; McShane H
    PLoS One; 2012; 7(12):e50447. PubMed ID: 23284637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.